依托尼秦 盐酸盐 | 2053-25-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 依托尼秦 盐酸盐
• 中文别名: 1-(二乙氨乙基)-2-(对乙氧基苄基)-5-硝基苯并咪唑；依托尼秦盐酸盐
• 英文名称: etonitazene hydrochloride
• 英文别名: 2-((4-Ethoxyphenyl)methyl)-N,N-diethyl-5-nitro-1H-benzimidazole-1-ethanamine hydrochloride；2-[2-[(4-ethoxyphenyl)methyl]-5-nitrobenzimidazol-1-yl]-N,N-diethylethanamine;hydrochloride
• CAS: 2053-25-0
• 化学式: C₂₂H₂₈N₄O₃*ClH
• 分子量: 432.95
• InChiKey: JTBRYBUIGVMMQL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.14
• 重原子数：
  30
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  77.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  依托尼秦 盐酸盐 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 反应 3.0h， 生成 1-[2-(diethylamino)ethyl]-2-(4-ethoxybenzyl)-1H-benzo[d]imidazol-5-amine
  参考文献：
  名称：

  Photoactivatable opiate derivatives as irreversible probes of the .mu.-opioid receptor

  摘要：

  The synthesis of aryldiazonium and arylazido derivatives of carfentanil, etonitazene, and naltrexone and of a triazaspirodecane derivative is described. The chemical stability and the spectral characteristics of these compounds were verified, and their binding affinity constants for the different opioid receptor classes were determined, in the absence of light, from competition experiments. With the exception of the naltrexyl derivatives, which remained nonselective, all compounds tested displayed a pronounced mu-binding selectivity with mu/delta and mu/kappa ratios ranging from 12 to 1000. After irradiation, only the arylazido probes led to an irreversible mu-binding-site inactivation. This inactivation fulfilled the criteria for photoaffinity labeling such as protection against inactivation by other opiate ligands and absence of an effect of scavengers on the extent of the inactivation. Most of the photoactivatable probes formed long-lasting reversible complexes with the opioid binding sites: an efficient dissociation procedure was thus required to discriminate between pseudoirreversible and covalent complexes. The marked differences in labeling efficacy between aryldiazonium salts and their corresponding arylazido derivatives are discussed.

  DOI：

  10.1021/jm00171a020

文献信息

• Octahydro-4a,7-ethano- and -etheno-benzofuro(3,2-e)isoquinoline derivatives
  申请人：E.I. DU PONT DE NEMOURS AND COMPANY

  公开号：EP0070427A2

  公开（公告）日：1983-01-26

  Compound of the formula wherin, R1 is -H, alkyl, -CH2R6, -C2H4 and -(CH2)nCN in which n = 1-3; R2 is -H, -OH, alkoxy and acyloxy; R3 is -H, alkyl, and -C(OH) (R4)R5; a is a single or double bond; R4 is -H, and alkyl; R5 is -H, alkyl, alkenyl, cycloalkyl, and -(CH2)mCeH5 in which m = 0-4 inclusive; R6 is , -C=CH, cycloalkyl, phenyl, 2-thienyl, 2-furyl, 2-tetrahydrofuryl, methyl substituted 2-furyl and methyl substituted 2-tetrahydrofuryl; R7 is -H, alkyl, -OCH3, -Cl, -Br and -F; and each of R8 and R9 is independently selected from the group consisting of -H, -CH3 and -Cl, exhibit analgesic, narcotic antagonist, mixed analgesic/narcotic antagonist, and/or anorexigenic properties.

  式中的化合物 其中 R1 是-H、烷基、- R6、-C2H4 和-(CH2)nCN，其中 n = 1-3； R2 是-H、-OH、烷氧基和酰氧基； R3 是-H、烷基和-C（OH）（R4）R5； a 是单键或双键； R4 是-H 和烷基； R5 是-H、烷基、烯基、环烷基和-( )mCeH5，其中 m = 0-4 （包括 0-4）； R6 是 C＝CH、环烷基、苯基、2-噻吩基、2-呋喃基、2-四氢呋喃基、甲基取代的 2-呋喃基和甲基取代的 2-四氢呋喃基； R7 是-H、烷基、-O 、-Cl、-Br 和-F；R8 和 R9 各自独立地选自由-H、-CH3 和-Cl 组成的组，具有镇痛、麻醉拮抗、混合镇痛/麻醉拮抗和/或厌食特性。
• Octahydro-4a,7-ethano- and -etheno-benzofuro[3,2-e]isoquinoline-4one derivatives
  申请人：E.I. DU PONT DE NEMOURS AND COMPANY

  公开号：EP0164136A1

  公开（公告）日：1985-12-11

  A compound of the formula wherein R1 is selected from the group consisting of -H, C1-10 alkyl, -CH2R6, n=1-3; and (̵CN2)nCN in which R2 is selected from the group consisting of -H, -OH, C1-2 alkoxy and C2-12 acyloxy of an alkanoic acid; R3 is selected from the group consisting of -H, C1-8 alkyl, and -C(OH) (R4)R5; a is a single or double bond; R4 is selected from the group consisting of -H, and C1-8 alkyl; R5 is selected from the group consisting of -H, C1-8 alkyl, C1-8 alkenyl, C1-8 cycloalkyl, and (CH2)mC6H5 in which m = 0,4 inclusive; R8 R6 is selected from the group consisting of , R9 -C≡CH, C3-6 cycloalkyl, phenyl, 2-thienyl, 2-furyl, 2-tetrahydrofuryl, methyl substituted 2-furyl and methyl substituted 2-tetrahydrofuryl; R7 is selected from the group consisting of -H, C1-3 alkyl, -OCH3, -CI, -Br and -F; and each of R8 and R9 is independently selected from the group consisting of -H, -CH3 and -Cl, X is R3, CO2R10, COR4 or COR5; and R10 is benzyl or lower alkyl, and a process for the preparation thereof.

  式中的化合物 式中 R1选自由-H、C1-10烷基、- R6、n=1-3； 和 (̵CN2)nCN 其中 R2 选自由-H、-OH、C1-2 烷氧基和 C2-12 烷氧基组成的组； R3 选自由-H、C1-8 烷基和-C(OH) (R4)R5 组成的组； a 是单键或双键； R4 选自-H 和 C1-8 烷基组成的组； R5 选自-H、C1-8 烷基、C1-8 烯基、C1-8 环烷基和 (CH2)mC6H5 组成的组，其中 m = 0，4 包括在内； R8 R6 选自以下组成的组 R9-C≡CH、C3-6 环烷基、苯基、2-噻吩基、2-呋喃基、2-四氢呋喃基、甲基取代的 2-呋喃基和甲基取代的 2-四氢呋喃基； R7 选自-H、C1-3 烷基、-O 、-CI、-Br 和-F 所组成的组；以及 R8 和 R9 各自独立地选自由-H、-CH3 和-Cl 组成的组、 X 是 R3、CO2R10、COR4 或 COR5；以及 R10 是苄基或低级烷基，及其制备方法。
• Alkoxyalkyl and alkylmer-captoalkyl substituted bridged benzofuroisoquinolines
  申请人：THE DU PONT MERCK PHARMACEUTICAL COMPANY

  公开号：EP0250855A1

  公开（公告）日：1988-01-07

  Alkoxyalkyl and alkylmercaptoalkyl substituted bridged benzofuroisoquinolines of formula wherein a is a single or double bond; R¹ is n-propyl or CH₂R⁵; R² is H, alkyl, acyl of an alkanoic acid, or R³ is H or alkyl; R⁴ is H, alkyl; alkenyl cycloalkyl or (CH₂)mC₆H₅ in which m is 0-4 inclusive; R⁵ is CH=C(R⁶) (R⁷). C≡CH, or cyclopropyl provided that when R⁵ is cyclopropyl, then R², R³ and R⁴ are independently H, and R⁸ is CH₃ or (CH₂)nC₆H₅ in which n is 3-4; R⁶ and R⁷ independently are H, CH₃ or Cl; R⁸ is alkyl, alkenyl cycloalkyl or (CH₂)nC₆H₅ is which n is 3-4; X is O or S; Y and Z independently are H, OR⁹, NHR⁹, or NR⁹R¹⁰, provided at least one of Y or Z is OR⁹, NHR⁹ , or NR⁹R¹⁰; R⁹ is H, alkyl or COR¹¹; R¹⁰ is alkyl or COR¹¹; and R¹¹ is H or alkyl have opioid antagonist, and/or appetite-controlling properties. Preferred compounds are kappa receptor selective antagonists.

  式中的烷氧基烷基和烷基巯基烷基取代桥联苯并呋异喹啉 其中 a 是单键或双键 R¹ 是正丙基或 CH₂R⁵； R² 是 H、烷基、酰基 的酰基 烷酸的酰基，或 R³ 是 H 或烷基； R⁴ 是 H、烷基、烯环烷基或 (CH₂)mC₆H₅，其中 m 为 0-4（包括 0-4）； R⁵ 是 CH=C(R⁶) (R⁷)。C≡CH，或环丙基，但当 R⁵ 为环丙基时，R²、R³ 和 R⁴ 独立地为 H，且 R⁸ 为 CH₃ 或 (CH₂)nC₆H₅ 其中 n 为 3-4； R⁶ 和 R⁷ 独立地为 H、CH₃ 或 Cl； R⁸ 是烷基、烯基环烷基或 (CH₂)nC₆H₅ ，其中 n 为 3-4； X 是 O 或 S Y 和 Z 独立地为 H、OR⁹、NHR⁹ 或 NR⁹R¹⁰，条件是 Y 或 Z 中至少有一个是 OR⁹、NHR⁹ 或 NR⁹R¹⁰； R𠞙 是 H、烷基或 COR¹¹； R¹⁰ 是烷基或 COR¹¹；和 R¹¹ 是 H 或烷基 具有阿片类拮抗剂和/或食欲控制特性。首选化合物是卡巴受体选择性拮抗剂。
• GALZI, JEAN-LUC;MEJEAN, ANNICK;ILIEN, BRIGITTE;MOLLEREAU, CATHERINE;MEUNI+, J. MED. CHEM., 33,(1990) N, C. 2456-2464
  作者：GALZI, JEAN-LUC、MEJEAN, ANNICK、ILIEN, BRIGITTE、MOLLEREAU, CATHERINE、MEUNI+

  DOI：——

  日期：——
• US4477456A
  申请人：——

  公开号：US4477456A

  公开（公告）日：1984-10-16